Inspirna, Inc.   Report issue

For profit Phase 1
Founded: New York NY United States (2010)

Organization Overview

First Clinical Trial
2016
NCT02922764
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Rgenix, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 1)

Digestive System Neoplasms (Phase 1)

Gastrointestinal Neoplasms (Phase 1)

Lymphoma (Phase 1)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 1)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 6